高级检索
    王先明, 唐静. Pembrolizumab对进展期PD-L1阳性三阴性乳腺癌患者的安全性和疗效评估[J]. 循证医学, 2017, 17(3): 146-149. DOI: 10.12019/j.issn.1671-5144.2017.03.007
    引用本文: 王先明, 唐静. Pembrolizumab对进展期PD-L1阳性三阴性乳腺癌患者的安全性和疗效评估[J]. 循证医学, 2017, 17(3): 146-149. DOI: 10.12019/j.issn.1671-5144.2017.03.007
    shu
    WANG Xian-ming, TANG Jing. The Safety and Therapeutic Effect Evaluation of Pembrolizumab in Patients with Advanced PD-L1 Positive Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 146-149. DOI: 10.12019/j.issn.1671-5144.2017.03.007
    Citation: WANG Xian-ming, TANG Jing. The Safety and Therapeutic Effect Evaluation of Pembrolizumab in Patients with Advanced PD-L1 Positive Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 146-149. DOI: 10.12019/j.issn.1671-5144.2017.03.007
    shu

    Pembrolizumab对进展期PD-L1阳性三阴性乳腺癌患者的安全性和疗效评估

    The Safety and Therapeutic Effect Evaluation of Pembrolizumab in Patients with Advanced PD-L1 Positive Triple Negative Breast Cancer

      摘要
      • HTML全文
      • 参考文献(12)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回